20 April 2009
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
Paltiel AD et al.
Clin Infect Dis 2009;48:806–15.
This study used a computer simulation of HIV acquisition, detection and care to model pre-exposure prophylaxis among men who have sex with men and are at high risk of HIV infection in the US.
In a cohort with a mean age of 34 years, lifetime HIV infection risk was reduced from 44% to 25% and mean life expectancy increased from 39.9 to 40.7 years.
Conclusion: In populations at high risk of HIV infection in the US, pre-exposure prophylaxis could substantially reduce the incidence of HIV transmission.
Link
20 April 2009
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals (Review).
Okwundu CI, Okoromah CAN.
The Cochrane Library 2009, Issue 1.
This review evaluated the effects of ARV pre-exposure prophylaxis for preventing HIV infection in high-risk individuals.
Only one trial met the criteria for this review but this was not completed as planned because two of the trial centres were closed prematurely.
The effectiveness of TDF in reducing the risk of acquiring HIV could not be evaluated conclusively because of the small number of HIV infections observed during the trial.
Conclusion: There is no reliable evidence to support the use of any ARV for HIV chemoprophylaxis.
Link
23 April 2009
HIV preexposure prophylaxis in the United States:
Paltiel AD et al.
Clin Infect Dis 2009;48:806–15.
• This study used a computer simulation of HIV acquisition, detection and care to model pre-exposure prophylaxis among men who have sex with men and are at high risk of HIV infection in the US.
• In a cohort with a mean age of 34 years, lifetime HIV infection risk was reduced from 44% to 25% and mean life expectancy increased from 39.9 to 40.7 years.
• Conclusion: In populations at high risk of HIV infection in the US, pre-exposure prophylaxis could substantially reduce the incidence of HIV transmission.
Link
28 April 2009
HIV preexposure prophylaxis in the United States:
Paltiel AD et al.
Clin Infect Dis 2009;48:806–15.
• This study used a computer simulation of HIV acquisition, detection and care to model pre-exposure prophylaxis among men who have sex with men and are at high risk of HIV infection in the US.
• In a cohort with a mean age of 34 years, lifetime HIV infection risk was reduced from 44% to 25% and mean life expectancy increased from 39.9 to 40.7 years.
• Conclusion: In populations at high risk of HIV infection in the US, pre-exposure prophylaxis could substantially reduce the incidence of HIV transmission.
Link
28 April 2009
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing
Okwundu CI, Okoromah CAN.
The Cochrane Library 2009, Issue 1.
• This review evaluated the effects of ARV pre-exposure prophylaxis for preventing HIV infection in high-risk individuals.
• Only one trial met the criteria for this review but this was not completed as planned because two of the trial centres were closed prematurely.
• The effectiveness of TDF in reducing the risk of acquiring HIV could not be evaluated conclusively because of the small number of HIV infections observed during the trial.
• Conclusion: There is no reliable evidence to support the use of any ARV for HIV chemoprophylaxis.
Link
Click on a category to access relevant articles
